Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform Continues expansion of global intellectual property c...
Anivive converts Laverdia-CA1 to full FDA approval First FDA-approved product to validate Anivive's AI-enabled development model — from drug rep...
LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Arrotex Pharmaceuticals Pty Ltd. (“Arrotex”) announced an exclusive license and commercialization ...
Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, announced a significant expansion of its Asia Pac...
IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. Maximum dose reached with no dose-limiting toxicities obser...
Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced so...
Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), is pleased to announ...
Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care chemo...
ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), is approved for use in Australia and Singapore as a first-...
BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Octane Biotech Inc., an Octane Medi...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endo...
Nelipak® Corporation (“Nelipak”), a leading global provider of healthcare packaging solutions, announced the opening of its new Asi...
Australian company Ferronova announced it has completed enrolment of patients for its two-year trial to progress commercialisation of FerroTrace, a ...
Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel trea...
© 2026 Biopharma Boardroom. All Rights Reserved.
